DHR · 10-Q · 2026Q3 · Full report

Geographic Revenue Performance

DANAHER CORP /DE/ · 2026-10-21 · Importance 30 · Surprise 40 · In source text

Developed-market sales increased 5% in the third quarter, but core sales were flat because mid-single-digit growth in Western Europe was offset by a low-single-digit decline in North America and weakness in other developed markets. High-growth-market sales increased 15% and core sales increased 10%, led by high-single-digit core sales growth in China, with high-growth markets representing approximately 31% of total third-quarter sales. Biotechnology growth was led by China and Western Europe, while North America declined year to date. Life Sciences growth was led by North America, Western Europe and China in the quarter and by Western Europe and China year to date; Diagnostics growth was led by high-growth markets in the quarter but declined year to date because of North America and China, with China improving year over year in the quarter.

Key facts

• Sales in high-growth markets increased year-over-year by 15% in the three-month period ended September 25, 2026 and core sales in such markets were up 10%. source
• High-growth markets represented approximately 31% of the Company’s total sales in the third quarter of 2026. source
• Of the $5.7 billion cash and cash equivalents as of September 25, 2026, approximately $1.8 billion was held within the U.S. and approximately $3.9 billion was held outside of the U.S. source
• Developed markets sales in the three-month period ended September 25, 2026 increased year-over-year by 5%, and core sales in developed markets were flat. source
• The Company conducts business and has a significant presence in China, Denmark, Germany, Singapore, Sweden, Switzerland and the United Kingdom in addition to the U.S. source

Impact estimates